Cumulus Neuroscience Presents Data at AAIC 2026 Annual Meeting Showing a Two-Minute Digital Task Matches or Outperforms Clinical Benchmarks for Alzheimer's Trial Pre-enrichment

ConferencepositiveNeuLogiq® PlatformPositive

AI Analysis

Summary

Cumulus Neuroscience presented data at AAIC 2026 demonstrating that its NeuLogiq® Platform two-minute Symbol Swap digital task achieved clinically meaningful discrimination between control, MCI and Alzheimer's dementia groups and detected blood-biomarker-defined pathology across three independent studies, supporting its use for trial pre-enrichment in Alzheimer's research.

Clinical Trial Data

Primary Endpoint

Met

Outcome Details

Two-minute Symbol Swap digital task demonstrated clinically meaningful discrimination between control, MCI and Alzheimer's dementia groups and detected blood-biomarker-defined pathology across three independent studies

Importance:6/10

Sentiment:

0.65

Alzheimer's diseasedigital biomarkerdiagnostic toolAAIC 2026neuroscienceMCIdementia

Read the original article

Published by PR Newswire Biotech on July 15, 2026 9:00 AM

Read Original